Novo Nordisk shares climbed 2.97% during the latest session, significantly outpacing the broader market. Trading volume was approximately 30% above its 30-day average, signaling heightened investor interest. Analysts attributed the rally to renewed optimism around the company’s obesity drug franchise and positive commentary from several research firms that maintained their “buy” and “hold” ratings this week.

The company announced a price cut of 15% for its flagship obesity treatment in the Chinese market, effective immediately. Management forecasts that the lower list price will expand patient access and could boost unit volumes by up to 25% within the next two quarters. While the move may weigh on near-term gross margins in China—currently 62% of regional pharmaceutical revenue—it underlines Novo Nordisk’s commitment to long-term market share growth in Asia’s fastest-growing healthcare sector.

Eldred Rock Partners LLC raised its position in Novo Nordisk by 11.5% during Q3, acquiring an additional 18,932 shares to bring its total to 184,151 shares, valued at roughly $10.2 million at period end. Cantor Fitzgerald Investment Advisors initiated a new stake of 23,325 shares worth about $1.29 million. Overall, hedge funds and other institutions now hold 11.54% of the company’s outstanding stock, reflecting growing confidence among large investors in the company’s mid-cycle growth trajectory.